

In April 2012 we were provided the below emails and attachments from TGA 1. I wanted to check with you whether there were any restrictions on how we can use this information?

Ideally, our legal section would like to use the emails and attachments in briefs of evidence that will go to ASADA's Anti-Doping Rule Violation Panel and they may also be presented at sporting tribunals if the matters progress to that stage.

Please give me a call on the numbers below if you have any questions.



Sent: 17 April 2012 11:37 AM

To: \$22

Subject: Fw: emails from the peptide distributor [SEC=IN-CONFIDENCE]

Hi \$22 and \$22 , we have had the below information supplied to us as the person was unaware that the peptides were illegal and is now very upset. He wants to help us with any info. If you see the email chain the supplier of the peptides is from your chart \$22 that \$22 spoke of. \$22 will be in contact with the informant and obtain the SMS messages. Regards \$22 PO Box 100, Woden ACT 2606

Thymosin is a family of naturally occurring peptides present in virtually all-human and animal cells, with Thymosin Beta 4 (TB4) being the most bio-active peptide. It is also found in the product Humanofort, which is sequenced in the embryonic extract. It is protein peptide that diminishes with cell age, in which restoration of levels rejuvenates the cell to function back to an optimum level as seen in a young matured cell, preventing cell death.

It does not function as, nor is it related to any growth factor or hormone in the body. It is a first class peptide candidate that promotes the following*:

WHAT THIS DOES:

- 1. Increases Red Blood Cells
- 2. Stops bleeding
- 3. Increase Endurance
- 4. Reduces Tie Up
- 5. Helps breathing
- 6. Reduces stomach acid which eliminates ulcers
- 7. Increases lean muscle mass
- 8. Helps repair tendons and ligaments
 - * Endothelial (blood vessels) cell differentiation (increases red blood cells)
 - * Angiogenesis (growth of new blood cells from pre-existing vessels) in dermal tissues
 - * Keratinocyte migration
 - * Collagen deposition; and
 - * Decreases inflammation.

It helps optimise and restore cell function therefore increasing cell signalling which in turn makes the body more efficient at producing the chemical actions it needs to sustain regeneration and energy needs.

One of Tß4 key mechanisms of action is its ability to regulate the cell-building protein, Actin, a vital component of cell structure and movement. Of the thousands of proteins present in cells, actin represents up to 10% of the total proteins which therefore plays a major role in the genetic makeup of the cell.

This potent peptide is a member of a ubiquitous family of 16 related molecules with a high conservation of sequence and localization in most tissues and circulating cells in the body. Tß4 not only binds to actin, but also blocks actin polymerization and is the actin-sequestering molecule in eukaryotic cells.

Tß4 was identified as a gene that was up-regulated four-to-six fold during early blood vessel formation and found to promote the growth of new blood cells from the existing vessels. This peptide is present in wound fluid and when administered, it promotes wound healing, muscle building and speeds up recovery time of muscles fibres and their cells. It also increases endurance and strength of muscle fibres making them function more efficiently, reducing lactic acid build up and fatigue, enabling the muscle to continually contract without becoming tired.

An additional key factor of Tß4 is that it promotes cell migration through a specific interaction with actin in the cell cytoskeleton. It has been demonstrated that a central small amino acid long-actin binding domain has both blood cell reproduction and wound healing characteristics. These characteristics are uncovered by accelerating the migration of endothelial cells and keratinocytes. It also increases the production of extracellular matrix-degrading enzymes.

Research confirms that Tß4 is a potent, naturally occurring wound repair factor with anti-inflammatory properties. Tß4 is different from other repair factors, such as growth factors, in that it promotes endothelial and keratinocyte migration. It also does not bind to the extracellular matrix and has a very low molecular weight meaning it can travel relatively long distances through tissues.

HOW TO USE: Give one 1ml vial subcutaneous each week for six consecutive weeks. There after use one 1ml injection per month. It's best to give injection 6 days before intense work.

PRICE: \$1200.00 per 3ml vial

Will have a look into it! Thanks for sending this through!

s 22 PO Box ^{s 22} HAWB 558669267997

I have done a couple of google checks and their appears to be an second with this name spelt Also a person that runs the website second but thought it interesting that an alternative drug website would import this peptide. Cheers second with this peptide.





"Important: This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information and has been sent in accordance with the TGA security policy.

If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly proh bited. If you receive this transmission in error please notify the author Immediately and delete all copies of this transmission."

From: \$ 22

To: FOI (FOI@health.gov.au)

Subject: Consultation on possible release of documents - ASADA [DLM=For-Official-Use-Only]

Date: Friday, 24 May 2019 10:08:50 AM

Attachments: ASADA FOI - Document for consultation.pdf

Dear Colleagues,

ASADA has received an FOI request for documents relating to an application being made to the Therapeutic Goods Administration (*TGA*) in August of 2015 to have the substance Thymosin Beta 4 scheduled.

The attached document has been captured by the scope of that request. I note that the attached document is a 2014 application by the National Integrity of Sport Unit (*NISU*) to the TGA along similar lines. It has been captured by the scope of the request due to being attached to an email discussing the 2015 application.

I would be grateful for any views the Department of Health may have on the potential release of the attached document under FOI. If the Department identifies any issues with the document being provided to the applicant could you please outline what potential harm may arise from such a course of action.

It at all possible it would be great if any response to be provided by **Friday 31 May 2019** to allow ASADA time to consider it prior to any decision on release being made. If that timeframe is not possible please just let me know as soon as possible so I can negotiate additional time with the applicant.

Please do not hesitate to contact me should you have any questions in relation to the above.

Kind regards,



Senior Lawyer Australian Sports Anti-Doping Authority

E s 22 @asada.gov.au

W www.asada.gov.au

"Important: This transmission is intended only for the use of the addressee and may contain Protected, confidential or legally privileged information. If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author immediately and delete all copies of this transmission."